U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 1099 results

Status:
US Approved OTC
Source:
21 CFR 331.11(i)(2) antacid:calcium-containing calcium (mono or dibasic salt)
Source URL:
First marketed in 1921
Source:
Syrup of Calcium Iodide N.F.
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Status:
Investigational
Source:
INN:bicozamycin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Bicyclomycin has been used to treat diarrhea in humans and bacterial diarrhea in calves and pigs and is marketed by Fujisawa (Osaka, Japan) under the trade name Bicozamycin. This drug is the selective inhibitor of rho, a member of the RecA-type ATPase class of enzymes that use nucleotide contacts to couple oligonucleotide translocation to ATP hydrolysis.
Status:
Investigational
Source:
NCT00247312: Phase 3 Interventional Completed Prostatic Neoplasm
(2005)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
NCT00352729: Not Applicable Interventional Withdrawn Burns
(2006)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN:CALCIUM CHLORIDE CA 45 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Calcium Cation Ca-45 is a calcium radioactive isotope which used for evaluation of calcium absorption and intracellular concentration in scientific research. There are several calcium radionuclides available, including 41Ca, 45Ca, and 47Ca. For practical reasons, 45Ca is the most commonly used calcium radionuclide for biological investigations.
Status:
Investigational
Source:
USAN:CALCIUM CHLORIDE CA 47 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Calcium Cation Ca-47 is a rare calcium radioactive isotope which used in orthopaedics for bone formation evaluation. Calcium-47 has a half-life of about five days, which is long enough for numerous biological investigations and short enough to ensure that the person subjected to the investigation is not under prolonged irradiation. It emits gamma rays in addition to beta rays, and since the gamma rays are capable of penetrating many centimeters of tissue, determination of calcium-47 in the body is possible by external measurements. Unfortunately, calcium-47 is difficult to produce and did not use in routine medical practice
Status:
Investigational
Source:
NCT01607385: Phase 1 Interventional Completed Diabetes Mellitus, Type 2
(2012)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

GSK-1614235 (mizagliflozin) is a sodium glucose co-transporter type 1 (SGLT1) inhibitor that has been investigated for treatment in type 2 diabetes. It is thought to suppress glucose absorption from the intestine in a way that is different from conventional type 2 diabetes drugs, thereby improving postprandial hyperglycemia. Phase 1 studies have been completed.
Status:
Investigational
Source:
Oncology. 2005;69(1):19-26.: Phase 3 Human clinical trial Completed Lymphoma, Non-Hodgkin/pathology
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Showing 11 - 20 of 1099 results